Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;2011:483851.
doi: 10.4061/2011/483851. Epub 2011 Mar 3.

Investigation of Differences in P53 Gene Polymorphisms Between Schizophrenia and Lung Cancer Patients in the Turkish Population

Free PMC article

Investigation of Differences in P53 Gene Polymorphisms Between Schizophrenia and Lung Cancer Patients in the Turkish Population

Ulku Ozbey et al. Genet Res Int. .
Free PMC article


Objective. The reduced incidence of cancer observed in schizophrenia patients may be related to differences in genetic background. It has been suggested that genetic predisposition towards schizophrenia is associated with reduced vulnerability to lung cancer, and p53 gene is one of the candidate genes. In our study, we aimed to investigate polymorphisms in the BstUI in exon 4 and MspI in intron 6 restriction sites of the p53 gene in Turkish schizophrenia patients, lung cancer patients, and controls. Material and Methods. Allele and genotype incidence of these polymorphisms with their haplotype combinations were studied in 100 Turkish lung cancer and schizophrenia patients and 100 controls without malignant and schizophrenia diseases. The genotype characteristics were determined by PCR-based RFLP method using DNA extracted from peripheral blood. Results. For the BstUI and MspI polymorphism, there were found significant differences in the genotype and allele frequencies between schizophrenia and lung cancer patients with control groups (P < .01). The analysis based on haplotype frequencies showed the presence of BstUI-MspI 2-1 haplotype in cancer patients (12%) in contrast to the absence of this haplotype in schizophrenia and controls. Only in lung cancer patients we found both significant decrease of A1 allele of the p53 codon 72 (OR 0.23, 95% CI 0.9-0.58) and A1/A1 homozygous genotype (P < .0001, OR 0.19). Conclusion. The results of this study suggest a protective effect of A1 allele against lung cancer, and the p53 MspI polymorphism may modify the susceptibility to lung cancer as a single factor rather than in combination with BstUI polymorphism.


Figure 1
Figure 1
Agaros gel electrophoresis of the p53 BstUI and the p53 MspI PCR products digested with BstUI and MspI restriction enzymes. (a) A1 allele does not create BstUI restriction site. The PCR product has 318 bp. Presence of CGCC sequence in A2 allele creates BstUI restriction site which leads to two fragments 182 bp and 136 bp. (b) A1 allele does not create MspI restriction site. The PCR product has 240 bp. Presence of CCGG sequence in A2 allele creates MspI restriction site which leads to two fragments 164 bp and 76 bp. Lanes 1, 6: 100 bp DNA ladder; lanes 2, 7: 1-1 homozygotes; lanes 3, 8: 1-2 heterozygotes; lanes 4, 9: 2-2 homozygotes; lane 5: no DNA in PCR reaction (blank).

Similar articles

See all similar articles

Cited by 5 articles


    1. Jablensky A. Schizophrenia and Cancer: is there a need to invoke a protective gene? Archives of General Psychiatry. 2001;58(6):579–580. - PubMed
    1. Gulbinat W, Dupont A, Jablensky A, et al. Cancer incidence of schizophrenic patients. Results of record linkage studies in three countries. The British Journal of Psychiatry. 1992;(18):75–83. - PubMed
    1. Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. Schizophrenia Research. 1994;12(3):185–194. - PubMed
    1. Catts VS, Catts SV. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophrenia Research. 2000;41(3):405–415. - PubMed
    1. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annual Review of Medicine. 1996;47:285–301. - PubMed